Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:13E,17-Octadecadienoic acid)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST000421 AN000663 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000421 AN000664 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000421 AN000665 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000421 AN000666 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000667 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000668 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000669 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000670 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000046 AN000078 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST000046 AN000079 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST000047 AN000080 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) Cerebrospinal fluid Human Alzheimers disease Mayo Clinic Raw MS Intensities
  logo